KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Short-term Investments: 2010-2025

Historic Short-term Investments for Nektar Therapeutics (NKTR) over the last 14 years, with Sep 2025 value amounting to $229.2 million.

  • Nektar Therapeutics' Short-term Investments rose 6.90% to $229.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $229.2 million, marking a year-over-year increase of 6.90%. This contributed to the annual value of $211.0 million for FY2024, which is 21.38% down from last year.
  • Latest data reveals that Nektar Therapeutics reported Short-term Investments of $229.2 million as of Q3 2025, which was up 72.42% from $132.9 million recorded in Q2 2025.
  • In the past 5 years, Nektar Therapeutics' Short-term Investments registered a high of $887.2 million during Q1 2021, and its lowest value of $132.9 million during Q2 2025.
  • Its 3-year average for Short-term Investments is $251.4 million, with a median of $240.6 million in 2024.
  • Its Short-term Investments has fluctuated over the past 5 years, first crashed by 49.18% in 2022, then increased by 6.90% in 2025.
  • Over the past 5 years, Nektar Therapeutics' Short-term Investments (Quarterly) stood at $708.7 million in 2021, then plummeted by 41.20% to $416.8 million in 2022, then tumbled by 35.61% to $268.3 million in 2023, then fell by 21.38% to $211.0 million in 2024, then increased by 6.90% to $229.2 million in 2025.
  • Its Short-term Investments was $229.2 million in Q3 2025, compared to $132.9 million in Q2 2025 and $179.7 million in Q1 2025.